ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2015 American Transplant Congress

    A 52-Week, Multicenter, Prospective, Observational, Non-Interventional, Open-Label Study to Assess the Effectiveness, Safety and Tolerability of Everolimus in Kidney Transplant Patients in Taiwan

    S.-M. Wang,1 P.-C. Lee,2 J.-D. Lian,3 K.-H. Shu,4 S.-T. Wu,5 H.-C. Chen,6 C.-C. Huang,7 M.-S. Wu,8 Y.-C. Tian,9 Y.-J. Chiang,10 Y.-T. Chen,11 H.-P. Wang.12

    1National Taiwan University Hospital, Taipei, Taiwan; 2National Cheng Kung University Hospital, Tainan, Taiwan; 3Chung Shan Medical University Hospital, Taichung, Taiwan; 4Taichung Veteran's General Hospital, Taichung, Taiwan; 5TriService General Hospital, Taipei, Taiwan; 6Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 7China Medical University Hospital, Taichung, Taiwan; 8Taipei Medical University Hospital, Taipei, Taiwan; 9ChangGung Memorial Hospital–Taipei, Taipei, Taiwan; 10ChangGung Memorial Hospital–LinKou, Taoyuan, Taiwan; 11ChangGung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan; 12E-Da Hospital, Kaohsiung, Taiwan.

    The study aimed to assess the clinical safety and tolerability of everolimus (EVR) in Taiwan kidney transplant patients.This study enrolled 203 kidney transplant recipients, between…
  • 2015 American Transplant Congress

    Impact of Subclinical Rejection (SCR) and Acute Clinical (ACR) in Renal Transplant Recipients

    R. Mehta, P. Sood, A. Cherukuri, S. Chen, G. Mour, C. Wu, N. Shah, C. Puttarajappa, P. Randhawa, A. Tevar, S. Hariharan.

    University of Pittsburgh Medical Center, Pittsburgh, PA.

    The importance of diagnosing subclinical rejection and its short and long term impact remains controversial.We prospectively evaluated 296 patients who had a kidney transplant at…
  • 2015 American Transplant Congress

    The use of Donation After Cardiac Death Liver Allografts does not increase Recurrence of Hepatocellular Carcinoma

    K. Croome, D. Lee, J. Burns, J. Nguyen, D. Perry, D. Harnois, C. Taner.

    Transplant, Mayo Clinic, Jacksonville, FL.

    Background: Previous studies examining the Scientific Registry of Transplant Recipients (SRTR) database for liver transplantation (LT) have demonstrated inferior survival for hepatocellular carcinoma (HCC) recipients…
  • 2015 American Transplant Congress

    Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment

    S. Radunz,1 T. Benkoe,1 J. Best,2 A. Bockisch,3 T. Lauenstein,4 H. Baba,5 A. Paul,1 J. Treckmann.1

    1General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany; 2Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany; 3Nuclear Medicine, University Hospital Essen, Essen, Germany; 4Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany; 5Pathology and Neuropathology, University Hospital Essen, Essen, Germany.

    Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability…
  • 2015 American Transplant Congress

    Risk Factors for Acute Cellular Rejection for Pediatric Kidney Transplant Recipients

    D. Cote,1 I. Bobanga,1 B. Vogt,2 K. Dell,2 R. Cunningham III,2 K. Noon,1 V. Humphreville,1 E. Sanchez,1 J. Schulak,1 K. Woodside.1

    1Department of Surgery, Case Western Reserve University & University Hospitals, Cleveland, OH; 2Department of Pediatrics, Case Western Reserve University & University Hospitals, Cleveland, OH.

    Background: Acute cellular rejection (ACR) potentially shortens the life of a kidney allograft. We sought to determine risk factors associated with the development of ACR…
  • 2015 American Transplant Congress

    Pregnancy Outcomes in Female Kidney Recipients Who Conceived Before Age 20

    L. Coscia,1 D. Armenti,1 S. Constantinescu,2 M. Moritz.1

    1National Transplantation Pregnancy Registry, Gift of Life Institute, Philadelphia; 2Medicine, Temple University School of Medicine, Philadelphia; 3Lehigh Valley Health Network, Allentown.

    The purpose of this study was to examine the pregnancy outcomes among female kidney recipients who conceived before age 20. Data were collected by the…
  • 2015 American Transplant Congress

    The Impact of Critical Illness and Pre-Transplant Hospitalization on Cost of Liver Transplantation

    S. Knechtle, L. Brummett, S. Perez.

    Surgery, Emory University School of Medicine, Atlanta, GA.

    In order to understand the cost impact of hospitalization and ICU admission immediately prior to liver transplantation (LT), we obtained all hospital costs associated with…
  • 2015 American Transplant Congress

    Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients

    L. Donohue, W. Ally, S. Dunn, J. Kennedy, J. Bergin.

    University of Virginia Health System, Charlottesville, VA.

    Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…
  • 2015 American Transplant Congress

    Racial Differences in Transplant and Waitlist Mortality Rates Among HIV+ Kidney Transplant Candidates

    J. Locke,1 S. Gustafson,2 C. Durand,3 J. Snyder,2 B. Shelton,1 R. Reed,1 P. MacLennan,1 S. Mehta,1 A. Nellore,1 D. Segev.2,3

    1University of Alabama, Birmingham, Birmingham, AL; 2SRTR, MMRF, Minneapolis, MN; 3Johns Hopkins Univerity, Baltimore, MD.

    Kidney transplant (KT) is now a viable option for select HIV+ end-stage renal disease patients. As OPTN does not collect HIV status at waitlisting, no…
  • 2015 American Transplant Congress

    Tolerant Kidney Transplant Patients Display B Cells With Regulatory Properties

    S. Brouard,1,2 M. Chesneau,1,3 L. Michel,1,2,3 E. Dugast,1,3 A. Chenouard,1,3 A. Pallier,1 D. Baron,1,3 J. Durand,1,3 F. Braza,1,3 P. Guerif,2 D.-A. Laplaud,1,2,3 J.-P. Soulillou,1,2,3 M. Giral,1,2,3 N. Degauque,1,3 E. Chiffoleau,1,3 S. Brouard.1,2

    1INSERM UMR 1064, Nantes, France; 2CHU de Nantes, ITUN, Nantes, France; 3Université de Nantes, Faculté de Médecine, Nantes, France.

    Whereas a B cell transcriptional profile has been recorded for operationally tolerant kidney graft patients, the role that B cells may play in this process…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 170
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences